Immusoft logo

Immusoft

immusoft.com

Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2009
Type
Corporation Seattle business license
Employees
21
Registered name
Immusoft Corp Seattle business license
Stage
Series B
Members see funding amounts.
.
Founders
Matthew Scholz

Is this your organization? Claim it

Immusoft explores scientific, ethical, regulatory, and practical considerations shaping pediatric cell and gene therapy clinical trial design

This article examines the scientific, ethical, regulatory, and practical factors that influence the design of pediatric cell and gene therapy (CGT) clinical trials, highlighting challenges and considerations specific to children. It aims to guide researchers and stakeholders in creating trials that balance safety, efficacy, and ethical responsibilities for pediatric populations.

Immusoft’s ISP-002 Earns FDA Rare Pediatric Disease Designation for MPS II, Enabling Potential Priority Review Voucher

Immusoft’s investigational engineered B cell therapy ISP-002 received FDA Rare Pediatric Disease designation for treating mucopolysaccharidosis type II (Hunter syndrome), making the program eligible for a Priority Review Voucher upon approval. ISP-002 is designed to use patients’ own B cells to continuously produce iduronate-2-sulfatase (IDS) as an alternative to frequent enzyme replacement infusions.

Immusoft Announces FDA Orphan Drug Designation for ISP-002, Engineered B Cell Therapy for MPS II

Immusoft received FDA Orphan Drug Designation for ISP-002, its investigational engineered B cell therapy for MPS II (Hunter syndrome), which programs patients' B cells to continuously produce the deficient enzyme IDS. The designation supports Immusoft’s broader engineered B cell platform strategy and highlights potential benefits over current enzyme replacement therapies, including sustained enzyme production and reduced treatment burden.

People

  • Sean Ainsworth
    Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
  • Scott McIvor Executive, Chief Development Officer

Online